This news release is available in French.
Culture
PHILADELPHIA (December 8, 2013) – According to Gertrude Stein, "A rose is a rose is a rose," but new research indicates that might not be the case when it comes to the rose's scent. Researchers from the Monell Center and collaborating institutions have found that as much as 30 percent of the large array of human olfactory receptor differs between any two individuals. This substantial variation is in turn reflected by variability in how each person perceives odors.
The addition of a monoclonal antibody called gemtuzumab combined with standard chemotherapy has been shown to significantly reduce the risk of relapse and increase rates of disease-free survival in pediatric patients with acute myeloid leukemia (AML). Post-treatment relapse rates are a major indicator of potential for long-term survival in children with the disease.
DETROIT – The majority of epilepsy patients who have brain surgery to treat their disorder are satisfied with the results in reducing epilepsy-related seizures and improving their psychological and social well-being.
Those were the conclusions of a new study by Henry Ford Hospital researchers who examined the medical records of epilepsy surgery patients and conducted a telephone survey to determine their satisfaction with the results of the procedure.
NEW ORLEANS— Adding bortezomib (Velcade) to standard preventive therapy for graft-versus-host-disease (GVHD) results in improved outcomes for patients receiving stem-cell transplants from mismatched and unrelated donors, according to researchers from Dana-Farber Cancer Institute.
NEW ORLEANS— Patients with myelodysplastic syndromes (MDS) who were as old as 74 fared as well with stem cell transplantation as did patients in the 60-to-65 age range, according to a study from Dana-Farber Cancer Institute presented at the annual meeting of the American Society of Hematology.
ATLANTA — Certain genetic alterations to the PAX gene family may be responsible for survival disparities seen between African-American and non-Latino white men with head and neck cancer, according to results presented here at the Sixth AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved, held Dec. 6-9.
(NEW ORLEANS, December 7, 2013) – Hematopoietic stem cell transplantation (HSCT), once considered an effective yet risky alternative to drug therapy for blood cancer, has become more accessible and successful in a wide range of patients as a result of major advances in transplant strategies and technologies. Several studies representing these advances were presented today during the 55th American Society of Hematology Annual Meeting and Exposition in New Orleans.
(NEW ORLEANS, December 7, 2013) – A series of advancements in genetically engineered cell therapies demonstrate early efficacy and safety in patients with blood disorders for whom standard treatments have been unsuccessful, according to data showcased today during the 55th American Society of Hematology (ASH) Annual Meeting and Exposition in New Orleans.
(NEW ORLEANS, December 7, 2013) – Hematopoietic stem cell transplantation (HSCT), once considered an effective yet risky alternative to drug therapy for blood cancer, has become more accessible and successful in a wide range of patients as a result of major advances in transplant strategies and technologies. Several studies representing these advances were presented today during the 55th American Society of Hematology Annual Meeting and Exposition in New Orleans.
The majority of all violent crime in Sweden is committed by a small number of people. They are almost all male (92%) who early in life develops violent criminality, substance abuse problems, often diagnosed with personality disorders and commit large number non-violent crimes. These are the findings of researchers at Sahlgrenska Academy who have examined 2.5 million people in Swedish criminal and population registers.
New York, NY, December 6, 2013 – Although the demand for infertility treatment is rising, the high cost may deter some couples from seeking care. Researchers from the University of California-San Francisco assessed direct out-of-pocket costs for couples undergoing fertility treatment. Those using medication only had the lowest out-of-pocket expenses at $912, while those using in vitro fertilization (IVF) had the highest at $19,234. The results, published in The Journal of Urology®, will help inform couples who seek infertility care and the physicians who counsel them.
Enzalutamide (trade name: Xtandi) has been approved since June 2013 for men with metastatic prostate cancer in whom the commonly used hormone blockade is no longer effective and who have already been treated with the cytostatic drug docetaxel. In an early benefit assessment pursuant to the Act on the Reform of the Market for Medicinal Products (AMNOG), the German Institute for Quality and Efficiency in Health Care (IQWiG) examined whether this new drug offers an added benefit over the appropriate comparator therapy specified by the Federal Joint Committee (G-BA).
WASHINGTON D.C. Dec. 6, 2013 -- To technology insiders, graphene is a certified big deal. The one-atom thick carbon-based material elicits rhapsodic descriptions as the strongest, thinnest material known. It also is light, flexible, and able to conduct electricity as well as copper. Graphene-based electronics promise advances such as faster internet speeds, cheaper solar cells, novel sensors, space suits spun from graphene yarn, and more.
A new study has found that leg ulcers take the same time to heal when people wear compression stockings rather than traditional bandages.
People in a trial, carried out by researchers from the universities of Manchester and York and funded by the National Institute for Health Research as part of their Health Technology Assessment programme (NIHR HTA), also reported less ulcer recurrence after using the stockings and required fewer nurse visits making the stockings better value for money for the NHS.